Smooth Drug Development February 2021 News Release
We are working on the following new projects:
• We signed a WO for CTD modules preparation with our global Sponsor.
• We signed 2 contracts for specification documents (INN: Vardenafil and INN: Fulvestrant).
We are happy to reach the following milestones in our projects:
• 90% of the sites were closed in the clinical trial with Risperidone.
• We prepared a CSR in the oncology clinical trial for patients with AML.
• Enrollment was started in a III phase trial with Nimesulide.
• Smooth finished all activities in a study with flu vaccine.